Drug
Aro Mmp7 Inhalation
Aro Mmp7 Inhalation: highest development phase Phase 1/2, developed by Arrowhead Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARO-MMP7 Inhalation Solution NCT05537025 | Phase 1/2 | Idiopathic Pulmonary Fibrosis |
Latest
No recent events.
Follow Aro Mmp7 Inhalation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.